![Feng Tian](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Feng Tian is the founder of LuxVitae Therapeutics, Inc. Prior to that, he served as Chairman, President & CEO of Ambrx, Inc. and Ambrx Biopharma Cayman, Inc. He received his undergraduate degree from Peking University and his doctorate from the University of Florida.
Anciens postes connus de Feng Tian
Sociétés | Poste | Fin |
---|---|---|
Ambrx Biopharma, Inc.
![]() Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Directeur Général | 15/08/2022 |
LuxVitae Therapeutics, Inc. | Fondateur | - |
AMBRX INC | Directeur Général | - |
Formation de Feng Tian
Peking University | Undergraduate Degree |
University of Florida | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
Ambrx, Inc.
![]() Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Ambrx Biopharma, Inc.
![]() Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
LuxVitae Therapeutics, Inc. |